Coronavirus

Actions

FDA researchers trying to decide when Americans should seek out a J&J booster

Johnson & Johnson COVID-19 Vaccine
Posted at 12:36 PM, Oct 13, 2021
and last updated 2021-10-13 12:40:16-04

WASHINGTON — The Food and Drug Administration is wrestling with how to decide when Americans should seek out a booster dose of the single-shot Johnson & Johnson COVID-19 vaccine.

Other manufacturers want to offer boosters six months after primary vaccination. But J&J proposed a range of times, from two months to six months.

In a review posted Wednesday, FDA scientists didn't reach a firm conclusion, citing shortcomings with J&J's data.

"Although not independently confirmed by FDA from datasets, summaries of the data suggest there may be a benefit in a second dose administered approximately 2 months after the primary dose, when compared to the efficacy seen in the pivotal study COV3001," researchers wrote in a 54-page document made public Wednesday.

According to CNBC, the report also indicated that a single dose of the J&J vaccine "still affords protection against severe COVID-19 disease and death in the United States."

On Thursday and Friday, an FDA advisory panel will recommend whether to back boosters of both the J&J and Moderna vaccines.

In documents released Tuesday, Moderna argued that a third dose of its vaccine was needed "six to eight months" after a second dose, The New York Times reports.

The FDA and CDC have already approved booster shots for the Pfizer COVID-19 vaccine for people aged 65 and older, for people with underlying medical conditions and for people who work essential jobs. The FDA says those Americans should seek out a Pfizer booster six months after their second dose.

Download our streaming app on your favorite device.  Click here for more.

Download our streaming app on your favorite device. Click here for more.